Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IPHA NASDAQ:NAGE NASDAQ:OCS NASDAQ:VALN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIPHAInnate Pharma$2.07+3.3%$2.04$1.29▼$3.51$190.35M0.2295,286 shs9,961 shsNAGENiagen Bioscience$9.68+0.7%$10.02$3.18▼$14.69$772.01M2.21936,658 shs686,426 shsOCSOculis$17.33-0.4%$17.67$11.78▼$23.08$756.66M0.2641,930 shs13,734 shsVALNValneva$8.93-0.1%$8.35$3.62▼$12.25$767.36M1.7870,298 shs76,469 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIPHAInnate Pharma0.00%-2.44%-6.32%+7.53%-11.50%NAGENiagen Bioscience0.00%+2.13%-4.09%-32.04%+170.70%OCSOculis0.00%+1.05%-2.79%-9.56%+45.73%VALNValneva0.00%+3.35%-22.46%+47.28%+40.02%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIPHAInnate Pharma$2.07+3.3%$2.04$1.29▼$3.51$190.35M0.2295,286 shs9,961 shsNAGENiagen Bioscience$9.68+0.7%$10.02$3.18▼$14.69$772.01M2.21936,658 shs686,426 shsOCSOculis$17.33-0.4%$17.67$11.78▼$23.08$756.66M0.2641,930 shs13,734 shsVALNValneva$8.93-0.1%$8.35$3.62▼$12.25$767.36M1.7870,298 shs76,469 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIPHAInnate Pharma0.00%-2.44%-6.32%+7.53%-11.50%NAGENiagen Bioscience0.00%+2.13%-4.09%-32.04%+170.70%OCSOculis0.00%+1.05%-2.79%-9.56%+45.73%VALNValneva0.00%+3.35%-22.46%+47.28%+40.02%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIPHAInnate Pharma 3.33Buy$11.00432.69% UpsideNAGENiagen Bioscience 3.00Buy$13.4238.64% UpsideOCSOculis 3.00Buy$35.75106.29% UpsideVALNValneva 3.00Buy$15.0067.97% UpsideCurrent Analyst Ratings BreakdownLatest IPHA, OCS, NAGE, and VALN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025VALNValnevaGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$14.00 ➝ $13.008/27/2025OCSOculisNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$36.008/25/2025VALNValnevaJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$14.008/25/2025VALNValnevaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.008/22/2025OCSOculisHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$32.00 ➝ $33.008/19/2025VALNValnevaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$18.008/11/2025NAGENiagen BioscienceHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$11.00 ➝ $12.007/28/2025IPHAInnate PharmaBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIPHAInnate Pharma$21.77M8.74N/AN/A$0.11 per share18.77NAGENiagen Bioscience$116.30M6.64$0.06 per share162.47$0.60 per share16.13OCSOculisN/AN/AN/AN/A$1.91 per shareN/AVALNValneva$183.52M4.18$0.10 per share91.50$2.41 per share3.71Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIPHAInnate Pharma-$53.53MN/A0.00∞N/AN/AN/AN/A9/17/2025 (Estimated)NAGENiagen Bioscience$8.55M$0.2146.10∞N/A15.24%23.12%15.53%N/AOCSOculis-$97.43M-$2.67N/AN/AN/A-13,958.12%-90.31%-67.85%11/6/2025 (Estimated)VALNValneva-$13.25M-$0.98N/AN/AN/A-33.87%-34.78%-13.43%11/6/2025 (Estimated)Latest IPHA, OCS, NAGE, and VALN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/21/2025Q2 2025OCSOculis-$0.53-$0.59-$0.06-$0.59$0.14 million$0.25 million8/12/2025Q2 2025VALNValneva-$0.27-$0.16+$0.11-$0.16$46.28 million$54.84 million8/6/2025Q2 2025NAGENiagen Bioscience$0.02$0.04+$0.02$0.04$28.55 million$31.12 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIPHAInnate PharmaN/AN/AN/AN/AN/ANAGENiagen BioscienceN/AN/AN/AN/AN/AOCSOculisN/AN/AN/AN/AN/AVALNValnevaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIPHAInnate Pharma2.522.602.60NAGENiagen BioscienceN/A3.883.24OCSOculis0.014.554.55VALNValneva0.662.271.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIPHAInnate Pharma0.16%NAGENiagen Bioscience15.41%OCSOculis22.30%VALNValneva11.39%Insider OwnershipCompanyInsider OwnershipIPHAInnate Pharma31.89%NAGENiagen Bioscience9.39%OCSOculisN/AVALNValneva14.91%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIPHAInnate Pharma22092.18 million62.79 millionNot OptionableNAGENiagen Bioscience12079.75 million72.26 millionN/AOCSOculis243.66 millionN/ANot OptionableVALNValneva70085.93 million73.12 millionNot OptionableIPHA, OCS, NAGE, and VALN HeadlinesRecent News About These CompaniesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALNSeptember 14 at 10:00 AM | globenewswire.comVaccine producer pledges to raise 10,000 for West Lothian charity partnerSeptember 13 at 3:40 PM | msn.comScotland’s largest vaccine producer pledges £10,000 to West Lothian charitySeptember 13 at 3:40 PM | msn.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALNSeptember 13 at 1:45 PM | prnewswire.comValneva SE Sponsored ADR (NASDAQ:VALN) Sees Significant Drop in Short InterestSeptember 13 at 11:17 AM | marketbeat.comValneva Scotland makes strides toward £10K fundraising goal in support of charity partner Team JakSeptember 12 at 10:26 AM | msn.comVALNEVA ALERT: Bragar Eagel & Squire, P.C. is Investigating Valneva SE on Behalf of Valneva Stockholders and Encourages Investors to Contact the FirmSeptember 11, 2025 | globenewswire.comValneva (NASDAQ:VALN) Stock Price Up 5.6% - Should You Buy?September 11, 2025 | marketbeat.comLevi & Korsinsky Launches Fraud Investigation on Behalf of Valneva SE (VALN) ShareholdersSeptember 10, 2025 | theglobeandmail.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALNSeptember 10, 2025 | globenewswire.comValneva (NASDAQ:VALN) Price Target Lowered to $13.00 at GuggenheimSeptember 10, 2025 | marketbeat.comValneva (NASDAQ:VALN) Price Target Cut to $13.00 by Analysts at GuggenheimSeptember 10, 2025 | americanbankingnews.comA Lyme Disease Vaccine’s Final Test Results Could Appear By Yearend.September 9, 2025 | msn.comValneva price target lowered to $13 from $14 at GuggenheimSeptember 9, 2025 | msn.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALNSeptember 8, 2025 | prnewswire.comShort Interest in Valneva SE Sponsored ADR (NASDAQ:VALN) Expands By 64.6%September 8, 2025 | marketbeat.comValneva (NASDAQ:VALN) Rating Increased to Hold at Wall Street ZenSeptember 8, 2025 | marketbeat.comValneva (NASDAQ:VALN) Raised to Hold at Wall Street ZenSeptember 8, 2025 | americanbankingnews.comValneva (NASDAQ:VALN) Trading Up 5% - Here's WhySeptember 5, 2025 | marketbeat.comVALNEVA Declaration of shares and voting rights: August 31, 2025September 5, 2025 | finance.yahoo.comVALNEVA ALERT: Bragar Eagel & Squire, P.C. is Investigating Valneva SE on Behalf of Valneva Stockholders and Encourages Investors to Contact the FirmSeptember 4, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 2025Buffett’s Cash Hoard Signals Market Caution, Value Plays EmergeBy Gabriel Osorio-Mazilli | August 19, 2025Why Sprouts Farmers Market is Buying $1 Billion of Its Own StockBy Gabriel Osorio-Mazilli | August 25, 2025IPHA, OCS, NAGE, and VALN Company DescriptionsInnate Pharma NASDAQ:IPHA$2.07 +0.07 (+3.50%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.Niagen Bioscience NASDAQ:NAGE$9.68 +0.07 (+0.73%) As of 04:00 PM EasternNiagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.Oculis NASDAQ:OCS$17.33 -0.07 (-0.40%) Closing price 04:00 PM EasternExtended Trading$17.26 -0.06 (-0.38%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.Valneva NASDAQ:VALN$8.93 -0.01 (-0.11%) Closing price 04:00 PM EasternExtended Trading$8.94 +0.01 (+0.06%) As of 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Wall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
